For the millions of people who have quietly endured chronic back pain while faithfully taking prescribed opioids, a Northwestern University study offers a sobering reckoning: years of daily medication appear to provide no meaningful relief beyond what untreated patients experience. Published in the journal Brain, the research does not condemn those who sought help through available means, but it does ask medicine to look more honestly at what long-term opioid therapy actually delivers — and to search, with new molecular tools now in hand, for something better.
Study: Long-term opioids don't improve chronic back pain outcomes
Years of this treatment had not moved the needle on their pain.
Mark
So the headline is that opioids don't work for chronic back pain. But the study says both groups had the same pain levels. Doesn't that mean opioids didn't make things worse?
Mimi
Right—that's the nuance. The opioid group wasn't suffering more. But they also weren't suffering less after 7.8 years of daily medication. So the question becomes: why take them if they're not helping?
Luke
But we need to be careful here. This is 70 people in one study. We don't know if they started opioids because their pain was worse, or if their pain would have gotten worse without the drugs. The study shows a snapshot, not causation.
Mark
Fair point. What about the brain findings? That seemed like the real discovery.
Mimi
The brain activity patterns were very different between the groups, especially in regions tied to reward and decision-making. But the brain structure itself was intact—no visible damage.
Luke
Which is important because it contradicts the fear that opioids destroy your brain. But different activity patterns—we should be honest about what that means. They found differences. They don't yet know if those differences are harmful, neutral, or even protective.
Mark
And the serotonin receptor markers—those could lead to new drugs?
Mimi
That's the hope. Eight patients in a rehab program who cut opioid use by 30 percent showed changes in those same markers. So the researchers think targeting serotonin might help both pain and tapering.
Luke
Again, eight people in a four-week program. That's preliminary. But it's a direction worth pursuing.
Mark
So what's the takeaway for someone on opioids right now?
Mimi
The study suggests that if you've been on them for years without improvement, there might be other options worth exploring. But this isn't saying opioids are dangerous—just that they may not be solving the problem they're prescribed for.
Luke
And we should note: these were supervised patients on low to moderate doses. The findings might not apply to people taking higher doses or without medical oversight.
El Pulso
- Roughly 5 million American adults take prescription opioids regularly for chronic pain, yet patients averaging nearly eight years of daily use reported pain scores virtually identical to those who took nothing at all.
- The finding disrupts a quiet assumption embedded in long-term prescribing: that sustained opioid use, even at low to moderate doses under physician supervision, must be doing some measurable good.
- Brain scans offered unexpected reassurance — opioid use had not visibly eroded brain structure — but revealed significant functional differences in the reward and decision-making networks, suggesting the brain is quietly reorganizing around the drug.
- A new computational method linking MRI data to neurotransmitter receptor maps has surfaced serotonin and opioid receptor signatures that may explain why some patients improve and others do not.
- In a small follow-up, patients who reduced opioid use by more than 30 percent showed brain changes tied to those same molecular markers, pointing toward a potential path for safer tapering and genuinely new treatments.
- Researchers now plan to test whether a serotonin-targeting antidepressant could address the underlying biology of chronic pain — a pivot from managing symptoms to rewriting the brain's relationship with them.
For the millions of people who have quietly endured chronic back pain while faithfully taking prescribed opioids, a Northwestern University study offers a sobering reckoning: years of daily medication appear to provide no meaningful relief beyond what untreated patients experience. Published in the journal Brain, the research does not condemn those who sought help through available means, but it does ask medicine to look more honestly at what long-term opioid therapy actually delivers — and to search, with new molecular tools now in hand, for something better.
A Northwestern University study of 140 chronic back pain patients has arrived at a counterintuitive conclusion: people who have taken prescription opioids daily for years experience no better pain relief than those who never took them. Comparing 70 long-term opioid users to 70 carefully matched patients with similar pain, researchers found both groups reporting nearly identical pain levels — around 5.4 on a 10-point scale — with the opioid group showing slightly worse physical and mental health outcomes. The patients had been on daily medication for an average of 7.8 years, under physician supervision, at low to moderate doses.
What the study did not find proved equally important. Brain imaging showed that years of opioid use had not visibly damaged brain structure, countering fears that long-term use inevitably causes lasting neurological harm. Yet functional MRI revealed striking differences in how brain regions communicated — particularly in the mesocorticolimbic network governing reward and motivation, and in the prefrontal cortex responsible for decision-making. The brain's architecture was intact; its working patterns were not.
To probe what was driving these differences, the research team developed a computational method combining MRI data with published maps of neurotransmitter receptors, uncovering molecular signatures in serotonin and opioid receptor activity linked to both chronic pain and long-term opioid use. When 21 patients moved through a four-week rehabilitation program and eight reduced their opioid use by more than 30 percent, their brain changes tracked those same markers — suggesting a molecular roadmap for new treatments and safer tapering strategies.
Based on these findings, Apkarian's team plans to test whether an antidepressant targeting the identified serotonin pathway could treat chronic pain and reduce opioid dependence. The study, supported by the NIH and the Department of Defense, is the first to examine how long-term opioid consumption shapes brain properties in chronic pain patients — and it opens a path toward therapies that might address pain's underlying biology rather than simply accompanying it, unchanged, for years.
A Northwestern University study of 140 chronic back pain patients has found something counterintuitive: people who have taken prescription opioids daily for years experience no better pain relief than those who never took the drugs at all. The research, published in October in the journal Brain, compared 70 long-term opioid users to 70 carefully matched patients with similar back pain who were not taking opioids. Both groups reported nearly identical pain levels, around 5.4 on a 10-point scale. The opioid group, if anything, showed slightly worse outcomes in physical function and mental health.
The patients taking opioids had been on daily prescription medication for an average of 7.8 years. These were not people experimenting with drugs or taking them without medical oversight—they were under physician supervision, taking low to moderate doses. Yet years of this treatment had not moved the needle on their pain. "The bad news is that we saw no sign that their pain had gotten any better by using this drug for so many years," said A. Vania Apkarian, director of the Center for Translational Pain Research at Northwestern's Feinberg School of Medicine. The finding matters because roughly 5 million American adults currently take prescription opioids regularly to manage chronic pain.
What makes the study significant is not just what it found about pain, but what it did not find about the brain. Researchers used functional MRI to examine both groups and discovered that years of opioid use had not visibly damaged brain structure—a reassuring finding given widespread concern that opioids cause lasting neurological harm. "The psychological and brain properties of the participants on long-term prescription opiates were essentially intact," Apkarian said. "That's good news because there's this fear nowadays that as soon as you start ingesting opiates, your brain is going to go crazy, and it doesn't."
But the brain activity patterns told a different story. When researchers looked at how brain regions functioned and communicated with each other, the differences between the two groups were striking. The mesocorticolimbic network—a system involved in reward and motivation—showed notably different activity in the opioid group. So did the prefrontal cortex, the region responsible for decision-making. These were not structural changes visible on a scan, but functional ones, measurable in how the brain was working.
To understand what was driving these differences, Apkarian's team developed a new computational method that combined the MRI data with published maps of neurotransmitter receptors in the brain. This technique allowed them to identify molecular signatures—distinct patterns of activity in serotonin and opioid receptors—that were associated with chronic pain and with long-term opioid use. "We identified molecular markers of different states of that brain in chronic pain patients," Apkarian said. "And this gives us clues for what kind of new treatments to pursue, what kind of drugs to try and what kind of drugs not to use."
The research team tested this insight by following 21 patients through a four-week pain rehabilitation program. Eight of them managed to reduce their opioid use by more than 30 percent. When researchers examined their brain activity, they found changes linked to the same serotonin and opioid receptor markers identified in the main study. This suggested that the molecular markers might serve as a guide for developing new treatments—both for chronic pain itself and for helping patients safely taper off opioids. Based on these findings, Apkarian's team plans to test whether an antidepressant that targets the serotonin pathway identified in the study could help treat chronic pain and reduce opioid dependence.
The study, titled "Multi-molecular adaptations of long-term opioid use in chronic pain," was supported by the National Institutes of Health and the U.S. Department of Defense. It represents the first research to examine how long-term opioid consumption affects brain properties in chronic pain patients. The work opens a path toward treatments that might actually address the underlying biology of pain without the years of medication that, this study suggests, may not be helping at all.
Citas Notables
We saw no sign that their pain had gotten any better by using this drug for so many years.— A. Vania Apkarian, director of the Center for Translational Pain Research at Northwestern University
We identified molecular markers of different states of that brain in chronic pain patients. And this gives us clues for what kind of new treatments to pursue.— A. Vania Apkarian
Quieres la nota completa?
Lee el original en News-Medical ↗